

Prior Authorization DRUG Guidelines

CETROTIDE® (Cetrorelix)

Effective Date: 7/28/05

Date Developed: 7/14/05 by C. Wilhelmy MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20,
8/3/21, 2/1/22, 1/31/23

Cetrotide is a Gonadotropin Releasing Hormone Antagonist. It competes with naturally occurring GnRH for binding on receptors of the pituitary. This delay luteinizing hormone surge, preventing ovulation until the follicles are of adequate size.

Pre-Authorization Criteria:

Controlled ovarian stimulation: Inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation

Note:

VCHCP requires that Cetrotide be prescribed by an infertility specialist and ultrasound monitoring to assess follicle size

DOSING: ADULTS

Controlled ovarian stimulation in conjunction with gonadotropins

(FSH, hMG): Female: SubQ: 0.25 mg once daily the morning or evening of stimulation day 5, or morning of stimulation day 6; continue 0.25 mg once daily until the day hCG is administered.

DOSING: ELDERLY — Not intended for use in women 65 years of age.

DOSING: RENAL IMPAIRMENT

Severe impairment: Use is contraindicated.

ADMINISTRATION — Cetrorelix is administered by SubQ injection following proper aseptic technique procedures. Injections should be to the lower abdomen, preferably around the navel (but staying at least 1 inch from the navel). The injection site should be rotated daily. The needle should be inserted completely into the skin at a 45-degree angle.

CONTRAINDICATIONS — Hypersensitivity to cetrorelix or any component of the formulation; extrinsic peptide hormones, mannitol, gonadotropin releasing hormone (GnRH) or GnRH analogs; severe renal impairment; pregnancy

PRECAUTIONS

Should only be prescribed by fertility specialists. Monitor carefully after first injection for possible hypersensitivity reactions. Use caution in women with active allergic conditions or a history of allergies; use in women with severe allergic conditions is not recommended. Pregnancy should be excluded before treatment is begun.

PREGNANCY

Use is contraindicated in females who are pregnant. Resorption resulting in fetal loss would be expected if used in a pregnant woman.

LACTATION — Excretion in breast milk unknown/not recommended

PATIENT EDUCATION

An instructional leaflet is provided for self-administration.

REFERENCES

1. Cetrotide (cetrorelix acetate) [prescribing information]. Rockland, MA: EMD Serono, Inc; May 2018.
2. Cetrotide (cetrorelix acetate) [product monograph]. Mississauga, Ontario, Canada: EMD Serono; June 2019.
3. UpToDate: Cetrorelix

Revision History:

Date Reviewed/Updated: 10/17/11 by A. Reeves MD

Date Reviewed/No Updates: 4/2/12; 1.16.13 by A. Reeves MD

Date Approved by P&T Committee: 7/28/05; 10/25/11; 4/24/12; 1/29/13 Date Reviewed/No

Updates: 1/28/14 by C. Sanders MD

Date Approved by P&T Committee: 1/28/14

Date Reviewed/Updated: 2/17/15 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/26/16
 Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/24/17
 Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/23/18
 Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/22/19
 Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 2/18/20
 Date Reviewed/ Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 8/3/21
 Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 2/1/22
 Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/31/23

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated Precautions Section, References, and formatting.
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review